IPO offerings shrink for Cancer Genetics and Singulex
This article was originally published in Clinica
Two diagnostic companies looking to launch on the public markets are now predicting more modest returns from their offerings than initially expected, underlining the current sluggish IPO climate and lukewarm investor appetite.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.